verapamil has been researched along with Body Weight in 74 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluates the clinical effectiveness of targeted arterial infusion of verapamil in interventional treatment of primary hepatocellular carcinoma." | 9.15 | Clinical evaluation of targeted arterial infusion of verapamil in the interventional chemotherapy of primary hepatocellular carcinoma. ( Duan, Q; Fan, P; Huang, J; Ji, C; Lin, X; Lv, Y; Qian, L; Yu, X, 2011) |
| "Our results suggest that FDTV is more effective than trandolapril in reducing proteinuria in normotensive, type 2 diabetic patients." | 9.11 | The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. ( Arceo-Navarro, A; Gomez-Harper, CT; Lozano-Nuevo, JJ; Rodriguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G, 2004) |
| "The effects of verapamil and bendrofluazide used singly and in combination were examined in patients with primary hypertension in a patient blind, partly observer blind placebo controlled study of parallel group design; there were ten subjects in each arm of the trial." | 9.06 | Verapamil and bendrofluazide in the treatment of hypertension: a controlled study of effectiveness alone and in combination. ( Benjamin, N; Phillips, RJ; Robinson, BF, 1988) |
| "Renal plasma flow, glomerular filtration rate plasma angiotensin II, aldosterone and arginine vasopressin, free water clearance, blood pressure and body weight in 11 patients with mild to moderate hypertension were determined at the end of consecutive 6 week periods of administration of placebo and verapamil up to 120 mg t." | 9.05 | Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, aldosterone and arginine vasopressin in essential hypertension. ( Danielsen, H; Pedersen, EB; Sørensen, SS; Thomsen, OO, 1985) |
| "In a double-blind, cross-over study for 6 weeks that included 28 patients with essential hypertension, WHO stage I-II, the hypotensive action of verapamil (160 mg thrice daily) was compared with nifedipine (20 mg slow release twice daily)." | 9.05 | Verapamil compared with nifedipine in the treatment of essential hypertension. ( Hals, O; Midtbø, K; van der Meer, J, 1982) |
| " In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure." | 7.70 | Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998) |
| "We have used the model of L-2-chloropropionic acid (L-CPA)-induced selective cerebellar granule necrosis to study excitatory amino acid-induced necrotic cell death in vivo produced by the activation of N-methyl-D-aspartate (NMDA) receptors." | 7.69 | L-2-chloropropionic acid-induced cerebellar granule cell necrosis is potentiated by L-type calcium channel antagonists. ( Gyte, A; Moores, R; Pitts, M; Smith, JC; Upton, R; Widdowson, PS; Wyatt, I, 1997) |
| "The possible alleviating effect of verapamil, a calcium entry blocker, on the resulting renal damage from the combination of a short episode of ischemia and CyA was studied in rats." | 7.67 | Calcium entry-blockade with verapamil in cyclosporine A plus ischemia induced acute renal failure in rats. ( Cohen, D; Eliahou, HE; Gavendo, S; Herzog, D; Iaina, A; Kapuler, S; Schiby, G; Serban, I, 1986) |
| "Heavy male Sprague-Dawley rats die of ventricular fibrillation within 2 to 3 h after isoproterenol administration." | 7.67 | Effects of antiarrhythmic agents on isoproterenol-induced ventricular fibrillation in heavy rats: a possible model of sudden cardiac death. ( Balazs, T; Ehrreich, SJ; el-Hage, AN; Johnson, GL, 1986) |
| "Adult male Wistar rats were used for studying the effect of Ca2+ antagonist verapamil on pulmonary hypertension, right ventricular hypertrophy and the medial thickness of pulmonary arterioles, induced by intermittent high altitude (IHA) hypoxia." | 7.66 | Effect of verapamil on pulmonary hypertension and right ventricular hypertrophy induced in rats by intermittent high altitude hypoxia. ( Ostádal, B; Pelouch, V; Procházka, J; Ressl, J; Urbanová, D; Widimský, J, 1981) |
| "Current guidelines for the treatment of hypertension do not provide specific recommendations for obese hypertensive patients." | 6.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "This study evaluates the clinical effectiveness of targeted arterial infusion of verapamil in interventional treatment of primary hepatocellular carcinoma." | 5.15 | Clinical evaluation of targeted arterial infusion of verapamil in the interventional chemotherapy of primary hepatocellular carcinoma. ( Duan, Q; Fan, P; Huang, J; Ji, C; Lin, X; Lv, Y; Qian, L; Yu, X, 2011) |
| "We sought to test the hypothesis that a fixed-dose combination of trandolapril/verapamil-SR (T/V) is superior to a fixed-dose combination of losartan/hydrochlorothiazide (L/H) on glucose tolerance in hypertensive patients with impaired glucose tolerance (IGT)." | 5.12 | Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. ( Bacher, P; Bakris, G; Fakouhi, K; Hewkin, A; Kipnes, M; Molitch, M; Sarafidis, P; Sowers, J, 2006) |
| "Our results suggest that FDTV is more effective than trandolapril in reducing proteinuria in normotensive, type 2 diabetic patients." | 5.11 | The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. ( Arceo-Navarro, A; Gomez-Harper, CT; Lozano-Nuevo, JJ; Rodriguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G, 2004) |
| "The effects of verapamil and bendrofluazide used singly and in combination were examined in patients with primary hypertension in a patient blind, partly observer blind placebo controlled study of parallel group design; there were ten subjects in each arm of the trial." | 5.06 | Verapamil and bendrofluazide in the treatment of hypertension: a controlled study of effectiveness alone and in combination. ( Benjamin, N; Phillips, RJ; Robinson, BF, 1988) |
| "In a double-blind, cross-over study for 6 weeks that included 28 patients with essential hypertension, WHO stage I-II, the hypotensive action of verapamil (160 mg thrice daily) was compared with nifedipine (20 mg slow release twice daily)." | 5.05 | Verapamil compared with nifedipine in the treatment of essential hypertension. ( Hals, O; Midtbø, K; van der Meer, J, 1982) |
| "Renal plasma flow, glomerular filtration rate plasma angiotensin II, aldosterone and arginine vasopressin, free water clearance, blood pressure and body weight in 11 patients with mild to moderate hypertension were determined at the end of consecutive 6 week periods of administration of placebo and verapamil up to 120 mg t." | 5.05 | Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, aldosterone and arginine vasopressin in essential hypertension. ( Danielsen, H; Pedersen, EB; Sørensen, SS; Thomsen, OO, 1985) |
| " In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure." | 3.70 | Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998) |
| "Calcium channel blockers, verapamil or felodipine, were given to genetically obese 6 and 11-month-old female SHHF/Mcc-facp (SHHF: Spontaneous Hypertension Heart Failure) rats for 8 weeks to investigate their effects on glucose and lipid metabolism and obesity." | 3.70 | Comparison of verapamil and felodipine treatment on lipid and glucose metabolism in obese female SHHF/Mcc-facp rats. ( Hoepf, T; McCune, SA; Park, SC; Radin, MJ, 1999) |
| "We compared the chronic effects in spontaneously hypertensive rats (SHR) of low doses of an angiotensin converting enzyme inhibitor, trandolapril, a Ca2+ channel antagonist, verapamil, and their combination (trandolapril-verapamil), on arterial mechanical properties, arterial wall hypertrophy and extracellular matrix proteins." | 3.70 | Prevention of arterial structural alterations with verapamil and trandolapril and consequences for mechanical properties in spontaneously hypertensive rats. ( Benetos, A; Kirchengaast, M; Koffi, I; Lacolley, P; Laurent, S; Pomiès, JP, 1998) |
| "We have used the model of L-2-chloropropionic acid (L-CPA)-induced selective cerebellar granule necrosis to study excitatory amino acid-induced necrotic cell death in vivo produced by the activation of N-methyl-D-aspartate (NMDA) receptors." | 3.69 | L-2-chloropropionic acid-induced cerebellar granule cell necrosis is potentiated by L-type calcium channel antagonists. ( Gyte, A; Moores, R; Pitts, M; Smith, JC; Upton, R; Widdowson, PS; Wyatt, I, 1997) |
| "The influence of age on the pharmacokinetics of verapamil at steady state has been studied in 74 individuals, age range 19-79 years, including healthy normotensive volunteers and patients with essential hypertension." | 3.68 | The influence of age on the pharmacokinetics of verapamil. ( Ahmed, JH; Elliott, HL; Meredith, PA, 1991) |
| "The antihypertensive efficacy of the calcium entry blocker nitrendipine administered as monotherapy (20-80 mg; mean, 36/day) on the average for 144 days to 46 patients with essential hypertension (WHO I and II) was investigated in relation to age, pretreatment blood pressure, and plasma renin activity." | 3.67 | Antihypertensive therapy with the long-acting calcium antagonist nitrendipine. ( Block, LH; Bolli, P; Bühler, FR; Erne, P; Kiowski, W; Müller, FB, 1984) |
| "Heavy male Sprague-Dawley rats die of ventricular fibrillation within 2 to 3 h after isoproterenol administration." | 3.67 | Effects of antiarrhythmic agents on isoproterenol-induced ventricular fibrillation in heavy rats: a possible model of sudden cardiac death. ( Balazs, T; Ehrreich, SJ; el-Hage, AN; Johnson, GL, 1986) |
| "The possible alleviating effect of verapamil, a calcium entry blocker, on the resulting renal damage from the combination of a short episode of ischemia and CyA was studied in rats." | 3.67 | Calcium entry-blockade with verapamil in cyclosporine A plus ischemia induced acute renal failure in rats. ( Cohen, D; Eliahou, HE; Gavendo, S; Herzog, D; Iaina, A; Kapuler, S; Schiby, G; Serban, I, 1986) |
| "To evaluate the mechanism of obesity-induced changes in pharmacokinetics and pharmacodynamics of verapamil observed in humans, single-dose and steady-state kinetic/dynamic studies in obese Zucker rats were done." | 3.67 | Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. ( Abernethy, DR; Todd, EL, 1986) |
| "Adult male Wistar rats were used for studying the effect of Ca2+ antagonist verapamil on pulmonary hypertension, right ventricular hypertrophy and the medial thickness of pulmonary arterioles, induced by intermittent high altitude (IHA) hypoxia." | 3.66 | Effect of verapamil on pulmonary hypertension and right ventricular hypertrophy induced in rats by intermittent high altitude hypoxia. ( Ostádal, B; Pelouch, V; Procházka, J; Ressl, J; Urbanová, D; Widimský, J, 1981) |
| "Current guidelines for the treatment of hypertension do not provide specific recommendations for obese hypertensive patients." | 2.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "Huntington disease is a neurodegenerative disease with complex pathophysiology." | 1.37 | Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats. ( Kalonia, H; Kumar, A; Kumar, P, 2011) |
| " This study was undertaken in adult male New Zealand rabbits to assess the effect of 3 weeks of dosing with NIS (1 mg." | 1.30 | A high cholesterol diet blocks the effect of calcium channel blockers on the uptake of sugars in rabbit intestine. ( Hyson, DH; Kappagoda, CT; Keelan, M; Thomson, AB, 1997) |
| "Nifedipine treatment completely reversed diabetes-induced prolongation in both time-to-peak tension and time-to-90% relaxation." | 1.29 | Influence of calcium channel blocker treatment on the mechanical properties of diabetic rat myocardium. ( Brown, RA; Lee, MM; Savage, AO; Sundareson, AM; Woodbury, DJ, 1996) |
| "In verapamil-treated rats (5 mg/kg/day), no histological or biochemical evidence of renal injury was detected." | 1.28 | Verapamil increases the nephrotoxic potential of gentamicin in rats. ( Fadali, GA; Farag, MM; Kandil, M, 1992) |
| "Verapamil treatment decreased ventricular pressure in experimental (P less than 0." | 1.28 | Effect of chronic verapamil treatment on ventricular function and growth in chick embryos. ( Clark, EB; Hansen, J; Hu, N; Litter, JE; Turner, DR, 1991) |
| "Verapamil was mixed with the food to provide a daily verapamil intake of 50 mg/kg body weight." | 1.27 | Effect of chronic verapamil therapy on cardiac norepinephrine and beta-adrenoceptor density. ( Buckley, DJ; Dillon, JS; Nayler, WG; Sturrock, WJ, 1988) |
| "Ibuprofen and verapamil treatment resulted in less myocardial damage after 48 h than placebo treatment but the differences were generally not statistically significant." | 1.27 | Evaluation of a rat model for assessing interventions to salvage ischaemic myocardium: effects of ibuprofen and verapamil. ( Evans, RG; Fischer, VW; Kulevich, J; Mueller, HS; Val-Mejias, JE, 1985) |
| "Nifedipine is a stronger inhibitor than verapamil as regards phagocytosis and enzyme release induced by A 23187 as well as chemotactic peptide, but with respect to fluoride-induced enzyme release verapamil was stronger inhibitor." | 1.26 | Interference of the calcium antagonists verapamil and nifedipine with lysosomal enzyme release from rabbit polymorphonuclear leukocytes. ( Elferink, JG, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (32.43) | 18.7374 |
| 1990's | 31 (41.89) | 18.2507 |
| 2000's | 14 (18.92) | 29.6817 |
| 2010's | 5 (6.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Szczepańska, K | 1 |
| Karcz, T | 1 |
| Kotańska, M | 1 |
| Siwek, A | 1 |
| Kuder, KJ | 1 |
| Latacz, G | 1 |
| Mogilski, S | 1 |
| Hagenow, S | 1 |
| Lubelska, A | 1 |
| Sobolewski, M | 1 |
| Stark, H | 1 |
| Kieć-Kononowicz, K | 1 |
| Zhang, J | 1 |
| Cao, H | 1 |
| Zhang, Y | 2 |
| Ma, J | 1 |
| Wang, J | 1 |
| Gao, Y | 1 |
| Zhang, X | 1 |
| Zhang, F | 1 |
| Chu, L | 1 |
| Balayssac, D | 1 |
| Cayre, A | 1 |
| Ling, B | 1 |
| Maublant, J | 1 |
| Penault-Llorca, F | 1 |
| Eschalier, A | 1 |
| Coudore, F | 1 |
| Authier, N | 1 |
| Huang, J | 1 |
| Duan, Q | 1 |
| Fan, P | 1 |
| Ji, C | 1 |
| Lv, Y | 1 |
| Lin, X | 1 |
| Qian, L | 1 |
| Yu, X | 1 |
| Satoh, E | 1 |
| Iwasaki, R | 1 |
| Kalonia, H | 1 |
| Kumar, P | 1 |
| Kumar, A | 1 |
| Sekiguchi, F | 1 |
| Kawata, K | 1 |
| Komori, M | 1 |
| Sunano, S | 1 |
| Bulgakov, VP | 1 |
| Tchernoded, GK | 1 |
| Mischenko, NP | 1 |
| Shkryl, YN | 1 |
| Glazunov, VP | 1 |
| Fedoreyev, SA | 1 |
| Zhuravlev, YN | 1 |
| Lehfeld, LS | 1 |
| Silveira, LA | 1 |
| Ghini, B | 1 |
| Lopes de Faria, JB | 1 |
| Rubio-Guerra, AF | 1 |
| Arceo-Navarro, A | 1 |
| Vargas-Ayala, G | 1 |
| Rodriguez-Lopez, L | 1 |
| Lozano-Nuevo, JJ | 1 |
| Gomez-Harper, CT | 1 |
| Bakris, G | 1 |
| Molitch, M | 1 |
| Hewkin, A | 1 |
| Kipnes, M | 1 |
| Sarafidis, P | 1 |
| Fakouhi, K | 1 |
| Bacher, P | 1 |
| Sowers, J | 1 |
| Scholze, J | 1 |
| Grimm, E | 1 |
| Herrmann, D | 1 |
| Unger, T | 1 |
| Kintscher, U | 1 |
| Kametaka, S | 1 |
| Kasahara, T | 1 |
| Ueo, M | 1 |
| Takenaka, M | 1 |
| Saito, M | 1 |
| Sakamoto, K | 1 |
| Nakahara, T | 1 |
| Ishii, K | 1 |
| Müller, FB | 1 |
| Bolli, P | 1 |
| Erne, P | 1 |
| Block, LH | 1 |
| Kiowski, W | 1 |
| Bühler, FR | 1 |
| Midtbø, K | 1 |
| Hals, O | 1 |
| van der Meer, J | 1 |
| Ostádal, B | 2 |
| Ressl, J | 1 |
| Urbanová, D | 1 |
| Procházka, J | 2 |
| Pelouch, V | 1 |
| Widimský, J | 1 |
| Aguas, AP | 1 |
| Nickerson, PA | 1 |
| Elferink, JG | 1 |
| Pedersen, KE | 1 |
| Dorph-Pedersen, A | 1 |
| Hvidt, S | 1 |
| Klitgaard, NA | 1 |
| Nielsen-Kudsk, F | 1 |
| Klugmann, S | 1 |
| Bartoli Klugmann, F | 1 |
| Decorti, G | 1 |
| Gori, D | 1 |
| Silvestri, F | 1 |
| Camerini, F | 1 |
| Grospietsch, G | 1 |
| Girndt, J | 1 |
| Fenske, M | 1 |
| Kuhn, W | 1 |
| Veksler, VI | 1 |
| Levitskaya, EL | 1 |
| Khatkevich, AN | 1 |
| Orekhova, IV | 1 |
| Khuchua, ZA | 1 |
| Kapelko, VI | 1 |
| Novosel, D | 1 |
| Lang, MG | 1 |
| Noll, G | 2 |
| Lüscher, TF | 3 |
| Conrad, K | 1 |
| Barbee, RW | 1 |
| Maymind, M | 1 |
| Zimmerman, R | 1 |
| Rossi, F | 1 |
| Filippelli, W | 1 |
| Russo, S | 1 |
| Filippelli, A | 2 |
| Berrino, L | 2 |
| Oh, HY | 1 |
| Fadda, GZ | 1 |
| Smogorzewski, M | 1 |
| Liou, HH | 1 |
| Massry, SG | 1 |
| Uehara, H | 1 |
| Nakaizumi, A | 1 |
| Baba, M | 1 |
| Iishi, H | 1 |
| Tatsuta, M | 1 |
| Soltis, EE | 1 |
| Newman, PS | 1 |
| Trowbridge, JL | 1 |
| Tanaka, Y | 2 |
| Kashiwagi, A | 2 |
| Saeki, Y | 1 |
| Takagi, Y | 2 |
| Asahina, T | 2 |
| Kikkawa, R | 1 |
| Shigeta, Y | 2 |
| Shaikh, MG | 1 |
| Heys, SD | 1 |
| Brown, PA | 1 |
| Whiting, PH | 1 |
| Johnson, PL | 1 |
| Bhattacharya, SK | 1 |
| Kaymaz, AA | 1 |
| Tan, H | 1 |
| Altuğ, T | 1 |
| Büyükdevrim, AS | 1 |
| Takase, H | 1 |
| Moreau, P | 1 |
| Küng, CF | 1 |
| Nava, E | 1 |
| Brown, RA | 1 |
| Lee, MM | 1 |
| Sundareson, AM | 1 |
| Woodbury, DJ | 1 |
| Savage, AO | 1 |
| Bauer, LA | 1 |
| Horn, JR | 1 |
| Pettit, H | 1 |
| Hyson, DH | 1 |
| Thomson, AB | 1 |
| Keelan, M | 1 |
| Kappagoda, CT | 1 |
| Widdowson, PS | 1 |
| Gyte, A | 1 |
| Upton, R | 1 |
| Smith, JC | 1 |
| Pitts, M | 1 |
| Moores, R | 1 |
| Wyatt, I | 1 |
| Priest, RM | 1 |
| Robertson, TP | 1 |
| Leach, RM | 1 |
| Ward, JP | 1 |
| Koffi, I | 1 |
| Lacolley, P | 1 |
| Kirchengaast, M | 1 |
| Pomiès, JP | 1 |
| Laurent, S | 1 |
| Benetos, A | 1 |
| Yoneda, H | 1 |
| Toriumi, W | 1 |
| Ohmachi, Y | 1 |
| Okumura, F | 1 |
| Fujimura, H | 1 |
| Nishiyama, S | 1 |
| López-Hernández, FJ | 1 |
| Carrón, R | 1 |
| Montero, MJ | 1 |
| Flores, O | 1 |
| López-Novoa, JM | 1 |
| Arévalo, MA | 1 |
| Adamcová, M | 1 |
| Kokstein, Z | 1 |
| Palicka, V | 1 |
| Vávrová, J | 1 |
| Kostál, M | 1 |
| Podholová, M | 1 |
| Kalous, P | 1 |
| Park, SC | 1 |
| Radin, MJ | 1 |
| Hoepf, T | 1 |
| McCune, SA | 1 |
| Gordon, EA | 1 |
| Guppy, LJ | 1 |
| Nair, RR | 1 |
| Nair, P | 1 |
| Mandarim-de-Lacerda, CA | 1 |
| Pereira, LM | 1 |
| Ruschitzka, F | 1 |
| Quaschning, T | 1 |
| deGottardi, A | 1 |
| Rossier, MF | 1 |
| Enseleit, F | 1 |
| Hürlimann, D | 1 |
| Shaw, SG | 1 |
| Masui, H | 1 |
| Wakabayashi, I | 1 |
| Siogawa, K | 1 |
| Koizumi, N | 1 |
| Bonhomme-Faivre, L | 1 |
| Forestier, F | 1 |
| Auchère, D | 1 |
| Soursac, M | 1 |
| Orbach-Arbouys, S | 1 |
| Farinotti, R | 1 |
| Kedziora-Kornatowska, K | 1 |
| Szram, S | 1 |
| Kornatowski, T | 1 |
| Szadujkis-Szadurski, L | 1 |
| Kedziora, J | 1 |
| Bartosz, G | 1 |
| Meneghelo, RS | 1 |
| Duprat, R | 1 |
| Batlouni, M | 1 |
| Severino, CA | 1 |
| Armaganijan, D | 1 |
| Magalhães, HM | 1 |
| Feher, J | 1 |
| Jasmin, G | 2 |
| Solymoss, B | 1 |
| Farag, MM | 1 |
| Kandil, M | 1 |
| Fadali, GA | 1 |
| Kolár, F | 1 |
| Seppet, EK | 1 |
| Vetter, R | 1 |
| Grünermel, J | 1 |
| Zilmer, K | 1 |
| Ashida, T | 1 |
| Kawano, Y | 1 |
| Yoshimi, H | 1 |
| Akabane, S | 1 |
| Kuramochi, M | 1 |
| Omae, T | 1 |
| Ogawa, T | 1 |
| Abe, N | 1 |
| Ikebuchi, M | 1 |
| Clark, EB | 1 |
| Hu, N | 1 |
| Turner, DR | 1 |
| Litter, JE | 1 |
| Hansen, J | 1 |
| Ahmed, JH | 1 |
| Meredith, PA | 1 |
| Elliott, HL | 1 |
| Wight, JP | 1 |
| Bassett, AH | 1 |
| Le Carpentier, JE | 1 |
| el Nahas, AM | 1 |
| Juneja, R | 1 |
| Gupta, I | 1 |
| Wali, A | 1 |
| Sanyal, SN | 1 |
| Chakravarti, RN | 1 |
| Majumdar, S | 1 |
| Whelton, PK | 1 |
| Watson, AJ | 1 |
| Kone, B | 1 |
| Fortuin, NJ | 1 |
| Nayler, WG | 2 |
| Dillon, JS | 2 |
| Sturrock, WJ | 1 |
| Buckley, DJ | 1 |
| Gu, XH | 1 |
| Angrisani, M | 1 |
| Loffreda, A | 1 |
| De Santis, D | 1 |
| De Paola, C | 1 |
| Maione, S | 1 |
| Matera, C | 1 |
| De Pasquale, M | 1 |
| Mauro, C | 1 |
| Blahos, J | 1 |
| Care, AD | 1 |
| Abbas, SK | 1 |
| Hughes, GS | 1 |
| Cowart, TD | 1 |
| Oexmann, MJ | 1 |
| Conradi, EC | 1 |
| Benjamin, N | 1 |
| Phillips, RJ | 1 |
| Robinson, BF | 1 |
| Baeyens, JM | 1 |
| Esposito, E | 1 |
| Ossowska, G | 1 |
| Samanin, R | 1 |
| Johnson, GL | 1 |
| Ehrreich, SJ | 1 |
| el-Hage, AN | 1 |
| Balazs, T | 1 |
| Iaina, A | 1 |
| Herzog, D | 1 |
| Cohen, D | 1 |
| Gavendo, S | 1 |
| Kapuler, S | 1 |
| Serban, I | 1 |
| Schiby, G | 1 |
| Eliahou, HE | 1 |
| Todd, EL | 1 |
| Abernethy, DR | 1 |
| Wikman-Coffelt, J | 1 |
| Sievers, R | 1 |
| Parmley, WW | 1 |
| Evans, RG | 1 |
| Val-Mejias, JE | 1 |
| Kulevich, J | 1 |
| Fischer, VW | 1 |
| Mueller, HS | 1 |
| Sørensen, SS | 1 |
| Thomsen, OO | 1 |
| Danielsen, H | 1 |
| Pedersen, EB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome[NCT00234858] | Phase 4 | 280 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Comparison of Single and Combination Diuretics in Low-Renin Hypertension[NCT02351973] | Phase 4 | 423 participants (Actual) | Interventional | 2009-11-30 | Active, not recruiting | ||
| A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes[NCT02887677] | Phase 4 | 85 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to On February 2019 Astra-Zeneca Greece decided to stop the financial support of the study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 trials available for verapamil and Body Weight
| Article | Year |
|---|---|
Clinical evaluation of targeted arterial infusion of verapamil in the interventional chemotherapy of primary hepatocellular carcinoma.
Topics: Antineoplastic Agents; Body Weight; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, | 2011 |
The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Body Weight; Calcium Channe | 2004 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Topics: Adult; Aged; Antihypertensive Agents; Appetite Depressants; Blood Pressure; Body Weight; Cyclobutane | 2007 |
Verapamil compared with nifedipine in the treatment of essential hypertension.
Topics: Adult; Body Weight; Calcium Channel Blockers; Creatinine; Double-Blind Method; Electrocardiography; | 1982 |
Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations.
Topics: Adult; Aged; Aged, 80 and over; Aging; Anti-Arrhythmia Agents; Body Weight; Calcium Channel Blockers | 1996 |
[Cycloergometric evaluation of the effects of verapamil in chronic coronary insufficiency].
Topics: Administration, Oral; Adult; Aged; Body Weight; Chronic Disease; Clinical Trials as Topic; Coronary | 1977 |
Verapamil and bendrofluazide in the treatment of hypertension: a controlled study of effectiveness alone and in combination.
Topics: Adult; Bendroflumethiazide; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Meth | 1988 |
Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, aldosterone and arginine vasopressin in essential hypertension.
Topics: Adult; Aldosterone; Angiotensin II; Arginine Vasopressin; Blood Pressure; Body Weight; Female; Glome | 1985 |
65 other studies available for verapamil and Body Weight
| Article | Year |
|---|---|
Optimization and preclinical evaluation of novel histamine H
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Proliferation; Dose-Response Relationship, Drug; D | 2018 |
Nephroprotective effect of calcium channel blockers against toxicity of lead exposure in mice.
Topics: Animals; Apoptosis; Blood Urea Nitrogen; Body Weight; Calcium Channel Blockers; Creatinine; Cytoprot | 2013 |
Vincristine-induced neuropathy in the rat is not modified by drug-drug interactions with the P-glycoprotein inhibitor verapamil.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Body Weight; Drug Interactions; Ma | 2008 |
Experimental diabetes attenuates calcium mobilization and proliferative response in splenic lymphocytes from mice.
Topics: Animals; Blood Glucose; Body Weight; Calcium; Calcium Channels, L-Type; Concanavalin A; Diabetes Mel | 2011 |
Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats.
Topics: Analysis of Variance; Animals; Apoptosis; Body Weight; Calcium Channel Blockers; Catalase; Cytokines | 2011 |
Caffeine-induced contracture in oesophageal striated muscle of normotensive and hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Caffeine; Calcium; Calcium Channel Blockers; Central Nervous S | 2003 |
Increase in anthraquinone content in Rubia cordifolia cells transformed by rol genes does not involve activation of the NADPH oxidase signaling pathway.
Topics: Anthraquinones; beta-Glucosidase; Body Weight; Calcium; Calcium Channels; Calcium Signaling; Cell Di | 2003 |
Early blood pressure normalization independent of the class of antihypertensive agent prevents augmented renal fibronectin and albuminuria in experimental diabetic nephropathy.
Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weigh | 2004 |
Effect of nifedipine on severe experimental cataract in diabetic rats.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Blockers; Cataract; Diabetes Me | 2008 |
Antihypertensive therapy with the long-acting calcium antagonist nitrendipine.
Topics: Adult; Aged; Blood Pressure; Body Weight; Calcium Channel Blockers; Female; Heart Rate; Humans; Hype | 1984 |
Effect of verapamil on pulmonary hypertension and right ventricular hypertrophy induced in rats by intermittent high altitude hypoxia.
Topics: Altitude Sickness; Animals; Body Weight; Cardiomegaly; Hematocrit; Hemodynamics; Hemoglobins; Hypert | 1981 |
Effect of verapamil on blood pressure and lesions in heart and kidney of rats made hypertensive by deoxycorticosterone (DOC).
Topics: Animals; Blood Pressure; Body Weight; Calcium; Coronary Vessels; Desoxycorticosterone; Drinking; Fem | 1983 |
Interference of the calcium antagonists verapamil and nifedipine with lysosomal enzyme release from rabbit polymorphonuclear leukocytes.
Topics: Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Exocytosis; Female; In Vitro Techniq | 1982 |
Digoxin-verapamil interaction.
Topics: Adult; Body Weight; Digoxin; Drug Interactions; Female; Half-Life; Humans; Kidney; Kinetics; Male; M | 1981 |
Adriamycin experimental cardiomyopathy in Swiss mice. Different effects of two calcium antagonistic drugs on ADM - induced cardiomyopathy.
Topics: Animals; Body Weight; Calcium Channel Blockers; Cardiomyopathies; Doxorubicin; Drug Interactions; Mi | 1981 |
[Pulmonary edema during tocolytic treatment (author's transl)].
Topics: Blood Proteins; Body Weight; Ethanolamines; Female; Fenoterol; Hematocrit; Hemoglobins; Humans; Obst | 1980 |
Myocardial adaptation to long-term action of substances associated with decreased intensity of cardiac function.
Topics: Adaptation, Physiological; Adenosine Triphosphatases; Animals; Body Weight; Calcium; Heart; Hypothyr | 1994 |
Endothelial dysfunction in aorta of the spontaneously hypertensive, stroke-prone rat: effects of therapy with verapamil and trandolapril alone and in combination.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Cerebrovascula | 1994 |
Effect of verapamil and captopril on endothelial injury in the diabetic hypertensive rat.
Topics: Animals; Blood Pressure; Blood Vessels; Body Weight; Captopril; Diabetes Mellitus, Experimental; End | 1994 |
Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances.
Topics: Animals; Aspirin; Body Weight; Calcium; Cardiomyopathies; Catecholamines; Cromolyn Sodium; Doxorubic | 1994 |
Abnormal leucine-induced insulin secretion in chronic renal failure.
Topics: Animals; Body Weight; Bridged Bicyclo Compounds; Creatinine; Glutamate Dehydrogenase; Glutaminase; I | 1994 |
Inhibition by verapamil of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats.
Topics: Animals; Anticarcinogenic Agents; Biomarkers, Tumor; Body Weight; Carcinogens; gamma-Glutamyltransfe | 1993 |
Differential cerebrovascular responsiveness in spontaneously hypertensive rats following antihypertensive treatment with clonidine and verapamil.
Topics: Animals; Blood Pressure; Body Weight; Cerebrovascular Circulation; Clonidine; Heart Rate; Hypertensi | 1993 |
Effects of verapamil on the cardiac alpha 1-adrenoceptor signalling system in diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Heart; Inosine Triphosphate; I | 1993 |
Chronic cyclosporin A (CsA) nephrotoxicity in the rat: the effect of calcium blockade with verapamil.
Topics: Animals; Blood Glucose; Body Weight; Cyclosporine; Kidney; Kidney Diseases; Male; Rats; Rats, Spragu | 1993 |
Regulation of membrane-mediated chronic muscle degeneration in dystrophic hamsters by calcium-channel blockers: diltiazem, nifedipine and verapamil.
Topics: Animals; Body Weight; Calcium; Calcium Channel Blockers; Cardiomegaly; Creatine Kinase; Cricetinae; | 1993 |
The effects of calcium channel blockers, verapamil, nifedipine and diltiazem, on metabolic control in diabetic rats.
Topics: Animals; Blood Glucose; Blood Proteins; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Ex | 1995 |
Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril.
Topics: Animals; Antihypertensive Agents; Arginine; Blood Pressure; Body Weight; Endothelium, Vascular; Hear | 1996 |
Influence of calcium channel blocker treatment on the mechanical properties of diabetic rat myocardium.
Topics: Analysis of Variance; Animals; Blood Glucose; Body Weight; Calcium Channel Blockers; Diabetes Mellit | 1996 |
A high cholesterol diet blocks the effect of calcium channel blockers on the uptake of sugars in rabbit intestine.
Topics: Animals; Biological Transport; Body Weight; Calcium Channel Blockers; Carbohydrates; Cholesterol, Di | 1997 |
L-2-chloropropionic acid-induced cerebellar granule cell necrosis is potentiated by L-type calcium channel antagonists.
Topics: Animals; Aspartic Acid; Body Weight; Calcium Channel Blockers; Cerebellar Diseases; Cerebellum; Drug | 1997 |
Membrane potential-dependent and -independent vasodilation in small pulmonary arteries from chronically hypoxic rats.
Topics: Animals; Body Weight; Cromakalim; Dinoprost; Dose-Response Relationship, Drug; Heart Ventricles; Hem | 1998 |
Prevention of arterial structural alterations with verapamil and trandolapril and consequences for mechanical properties in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antigens, CD; Aorta, Thoracic; Arteries; Blood Pr | 1998 |
Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats.
Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; B | 1998 |
Antihypertensive effect of trandolapril and verapamil in rats with induced hypertension.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Body Weight; Drug Synergism; Fema | 1999 |
Cardiac troponin T in pregnant women having intravenous tocolytic therapy.
Topics: Adult; Apgar Score; Body Weight; Enzyme-Linked Immunosorbent Assay; Female; Fenoterol; Fetal Blood; | 1999 |
Comparison of verapamil and felodipine treatment on lipid and glucose metabolism in obese female SHHF/Mcc-facp rats.
Topics: Age Factors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Calcium C | 1999 |
Cardiomyopathic changes in streptozotocin-induced diabetes.
Topics: Adenosine Triphosphatases; Animals; Body Weight; Calcium Channel Blockers; Cardiomyopathies; Cardiot | 1999 |
Age-dependent variation in contractility of adult cardiac myocytes.
Topics: Aging; Animals; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T | 2001 |
Heart biometry and allometry in rats submitted to nitric oxide synthesis blockade and treatment with antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Body Weight; Enalapril; Heart; Heart Ventricles; Male; NG-Nitroarg | 2001 |
Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Acetylcholine; Animals; Blood Pressure; Body Weight; Cells, C | 2001 |
Diminished inibitory action of ethanol on the contraction of gallbladder isolated from chronically ethanol-fed Guinea pigs.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2002 |
Chronic administration of verapamil, ketoconazole and carbamazepine: impact on immunological parameters.
Topics: Animals; Anticonvulsants; Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1 | 2002 |
The effect of verapamil on the antioxidant defence system in diabetic kidney.
Topics: Albuminuria; Animals; Antioxidants; Basement Membrane; Blood Glucose; Body Weight; Catalase; Diabete | 2002 |
Prevention of hereditary cardiomyopathy in the hamster by verapamil and other agents.
Topics: Animals; Body Weight; Calcium; Cardiomyopathies; Cell Membrane; Cinnarizine; Creatine Kinase; Cricet | 1975 |
Verapamil increases the nephrotoxic potential of gentamicin in rats.
Topics: Animals; Blood Urea Nitrogen; Body Weight; Creatinine; Drug Interactions; Gentamicins; Injections, I | 1992 |
Thyroid control of contractile function and calcium handling in neonatal rat heart.
Topics: Animals; Animals, Newborn; Body Weight; Calcium; Male; Myocardial Contraction; Myocardium; Rats; Rat | 1992 |
Effects of ouabain and verapamil on endothelin-1-induced contraction of mesenteric artery in young spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Endothelins; Heart Rate; Hypertension; In Vitro Techniques; Is | 1991 |
Effect of verapamil on cardiac protein kinase C activity in diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Heart Ventricles; Insulin; Mal | 1991 |
Effect of chronic verapamil treatment on ventricular function and growth in chick embryos.
Topics: Animals; Body Weight; Chick Embryo; Embryonic and Fetal Development; Heart; Hemodynamics; Myocardium | 1991 |
The influence of age on the pharmacokinetics of verapamil.
Topics: Adult; Aged; Aging; Body Weight; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Hy | 1991 |
Effect of treatment with enalapril, verapamil and indomethacin on compensatory renal growth in the rat.
Topics: Animals; Body Weight; Enalapril; Hypertrophy; Indomethacin; Kidney; Male; Nephrectomy; Organ Size; R | 1990 |
Effect of verapamil on different spermatozoal functions in guinea pigs--a preliminary study.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Body Weight; Calcium Channel Blockers; Female | 1990 |
Calcium channel blockade in dialysis patients with left ventricular hypertrophy and well-preserved systolic function.
Topics: Aged; Blood Pressure; Body Weight; Cardiomegaly; Cardiomyopathy, Dilated; Echocardiography; Female; | 1987 |
Effect of chronic verapamil therapy on cardiac norepinephrine and beta-adrenoceptor density.
Topics: Anesthetics; Animals; Body Weight; Diet; Dihydroalprenolol; Heart; Male; Myocardium; Norepinephrine; | 1988 |
Effect of age and of hypertrophy on cardiac Ca2+ antagonist binding sites.
Topics: Aging; Animals; Blood Pressure; Body Weight; Calcium Channels; Cardiomegaly; Cell Membrane; Dihydrop | 1989 |
Interference of prenatal and postnatal exposure to Ca2+-antagonist agents on rat functional development of vascular system.
Topics: Acetylcholinesterase; Animals; Animals, Newborn; Blood Pressure; Body Weight; Calcium Channel Blocke | 1989 |
Comparison of effects of verapamil, low calcium diet and betamethasone on duodenal calcium absorption efficiency in the chick.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Administration, Oral; Animals; Betamethasone; Body Weight; | 1989 |
Verapamil-induced natriuretic and diuretic effects: dependency on sodium intake.
Topics: Adult; Blood Pressure; Body Weight; Calcium; Diuresis; Female; Humans; Male; Middle Aged; Natriuresi | 1988 |
Effects of peripheral and central administration of calcium channel blockers in the naloxone-precipitated abstinence syndrome in morphine-dependent rats.
Topics: Animals; Body Weight; Brain; Calcium Channel Blockers; Clonidine; Diarrhea; Flunarizine; Injections, | 1987 |
Effects of antiarrhythmic agents on isoproterenol-induced ventricular fibrillation in heavy rats: a possible model of sudden cardiac death.
Topics: Animals; Anti-Arrhythmia Agents; Body Weight; Bretylium Tosylate; Death, Sudden; Disease Models, Ani | 1986 |
Calcium entry-blockade with verapamil in cyclosporine A plus ischemia induced acute renal failure in rats.
Topics: Acute Kidney Injury; Animals; Body Weight; Cyclosporins; Female; Ischemia; Kidney; Kidney Function T | 1986 |
Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats.
Topics: Animals; Blood Pressure; Blood Proteins; Body Weight; Disease Models, Animal; Female; Kinetics; Obes | 1986 |
Verapamil preserves adenine nucleotide pool in cardiomyopathic Syrian hamster.
Topics: Adenine Nucleotides; Animals; Body Weight; Collagen; Cricetinae; Disease Models, Animal; Heart Failu | 1986 |
Evaluation of a rat model for assessing interventions to salvage ischaemic myocardium: effects of ibuprofen and verapamil.
Topics: Animals; Body Weight; Creatine Kinase; Disease Models, Animal; Ibuprofen; Male; Myocardial Infarctio | 1985 |